Undisclosed Autoimmune Program

About Replicate Bioscience

Replicate Bioscience is a private, pre-revenue biotech firm developing a proprietary self-replicating RNA (srRNA) platform. The technology is engineered to use the cell's own machinery to repeatedly produce therapeutic RNA, leading to significantly higher and more durable protein expression than standard mRNA. The company is advancing a pipeline of srRNA candidates across infectious disease, oncology, and autoimmune indications, positioning itself to address limitations of current RNA therapeutics. Recent milestones include grant funding for vaccine development and key leadership appointments.

About TianTi Biotherapeutics

TianTi Biotherapeutics is a private, preclinical-stage biotech developing T-cell therapies for oncology and autoimmune indications. As a pre-revenue company, it is likely funded by venture capital and is building its technology platform and pipeline. Its strategic location in the Cambridge biotech hub provides access to talent and potential collaborators, positioning it in the competitive but high-potential cell therapy space.

Therapeutic Areas

Other Autoimmune Disorder Drugs